Ibrutinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4360 publications

Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial.

Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial.

Journal: AME clinical trials review
Published: June 22, 2026

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

Journal: Leukemia & lymphoma
Published: June 21, 2026

The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.

The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.

Journal: Expert opinion on drug discovery
Published: June 15, 2026

BTK inhibition enhances immunovirotherapy in glioblastoma via tertiary lymphoid structure modulation.

BTK inhibition enhances immunovirotherapy in glioblastoma via tertiary lymphoid structure modulation.

Journal: bioRxiv : the preprint server for biology
Published: June 12, 2026

Radiation recall dermatitis following ibrutinib therapy in a patient with breast cancer and non-Hodgkin lymphoma.

Radiation recall dermatitis following ibrutinib therapy in a patient with breast cancer and non-Hodgkin lymphoma.

Journal: BMJ case reports
Published: June 10, 2026

Ibrutinib improves overall survival in patients with mantle cell lymphoma.

Ibrutinib improves overall survival in patients with mantle cell lymphoma.

Journal: Nature reviews. Clinical oncology
Published: June 03, 2026

Where next for BTKi-BCL2i combinations in mantle cell lymphoma?

Where next for BTKi-BCL2i combinations in mantle cell lymphoma?

Journal: British journal of haematology
Published: June 01, 2026

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.

Journal: Expert opinion on pharmacotherapy
Published: May 29, 2026

Long-term outcomes of first-line iFCR regimen in chronic lymphocytic leukemia/small lymphocytic lymphoma and the role of MRD

Long-term outcomes of first-line iFCR regimen in chronic lymphocytic leukemia/small lymphocytic lymphoma and the role of MRD

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: May 20, 2026

Clinical Safety Profile of Bruton's Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India.

Clinical Safety Profile of Bruton's Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India.

Journal: Cureus
Published: May 19, 2026

Cyclin-Dependent Kinase 5 Contributes to Bruton's Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell Lymphoma.

Cyclin-Dependent Kinase 5 Contributes to Bruton's Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell Lymphoma.

Journal: Research square
Published: May 18, 2026

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.

Journal: bioRxiv : the preprint server for biology
Published: May 18, 2026
Showing 1-12 of 4,360

Last Updated: 06/30/2026